See more : ABG Acquisition Corp. I (ABGI) Income Statement Analysis – Financial Results
Complete financial analysis of Alpine Immune Sciences, Inc. (ALPN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpine Immune Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MJ Harvest, Inc. (MJHI) Income Statement Analysis – Financial Results
- Cox & Kings Financial Service Limited (CKFSL.NS) Income Statement Analysis – Financial Results
- Heliogen, Inc. (HLGN-WT) Income Statement Analysis – Financial Results
- Pherecydes Pharma Société anonyme (ALPHE.PA) Income Statement Analysis – Financial Results
- CJ Cheiljedang Corporation (097955.KS) Income Statement Analysis – Financial Results
Alpine Immune Sciences, Inc. (ALPN)
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.88M | 30.06M | 23.44M | 9.34M | 1.74M | 705.00K | 1.73M | 2.95M | 492.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 80.90M | 597.00K | 620.00K | 27.19M | 35.85M | 28.97M | 10.63M | 143.00K | 66.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.03M | 29.47M | 22.82M | -17.85M | -34.11M | -28.27M | -8.90M | 2.81M | 426.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -37.41% | 98.01% | 97.36% | -191.22% | -1,960.17% | -4,009.22% | -513.86% | 95.15% | 86.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.90M | 70.24M | 58.74M | 27.19M | 35.85M | 28.97M | 10.63M | 23.32M | 16.05M | 12.20M | 13.14M | 7.10M |
| General & Administrative | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Other Expenses | 0.00 | -97.00K | -4.00K | 1.33M | 812.00K | 1.20M | 0.00 | 0.00 | 80.00K | 296.34K | 0.00 | 150.94K |
| Operating Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Cost & Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Interest Income | 11.85M | 3.29M | 259.00K | 245.00K | 1.25M | 1.30M | 542.00K | 439.00K | 80.00K | 0.00 | 10.00K | 0.00 |
| Interest Expense | 98.00K | 476.00K | 816.00K | 775.00K | 338.00K | 319.00K | 152.00K | 0.00 | 0.00 | 845.10K | 931.00K | 694.07K |
| Depreciation & Amortization | 576.00K | 3.19M | 255.00K | 1.58M | 2.06M | 388.00K | 241.00K | 143.00K | 66.00K | 86.44K | 219.00K | 212.03K |
| EBITDA | -43.67M | -54.96M | -49.60M | -27.17M | -41.51M | -35.33M | -14.19M | -31.90M | -22.90M | -14.10M | -15.05M | -8.67M |
| EBITDA Ratio | -74.18% | -182.80% | -211.59% | -291.07% | -2,385.86% | -5,011.49% | -819.82% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Operating Income | -44.25M | -58.15M | -49.86M | -28.75M | -43.57M | -37.83M | -14.97M | -31.90M | -22.90M | -14.49M | -15.28M | -9.03M |
| Operating Income Ratio | -75.16% | -193.41% | -212.68% | -307.97% | -2,504.25% | -5,365.96% | -865.05% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.17M | 2.72M | -561.00K | 803.00K | 1.72M | 977.00K | 6.99M | 439.00K | 80.00K | -548.76K | -921.00K | -543.14K |
| Income Before Tax | -32.08M | -55.43M | -50.42M | -27.95M | -41.85M | -36.85M | -7.98M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Income Before Tax Ratio | -54.49% | -184.38% | -215.07% | -299.37% | -2,405.29% | -5,227.38% | -461.18% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 103.00K | 2.33M | -87.00K | -6.00K | 682.00K | -366.00K | -200.00K | -143.00K | -66.00K | 1.14M | 941.00K | 845.01K |
| Net Income | -32.18M | -57.76M | -50.33M | -27.94M | -42.53M | -36.49M | -7.78M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Net Income Ratio | -54.66% | -192.13% | -214.70% | -299.30% | -2,444.48% | -5,175.46% | -449.62% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| EPS Diluted | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| Weighted Avg Shares Out | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
Does Alpine Immune Sciences, Inc. (ALPN) Have the Potential to Rally 25.38% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might...
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the second quarter ended June 30, 2023. “During the first...
Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue?
Alpine Immune has been riding on positive momentum surrounding its under-development drug program.
Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers,...
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers,...
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers,...
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023. “So far this year, we have...
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023. “So far this year, we have...
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the 2023 Bank of America Securities Healthcare Conference. Date: Tuesday,...
Source: https://incomestatements.info
Category: Stock Reports